Hello,
Welcome to Insider Healthcare. I'm healthcare editor Leah Rosenbaum, and today in healthcare news:
- The FDA has authorized a low-dose version of the Pfizer/BioNTech COVID-19 vaccine for kids aged 5-11;
- Samsung has a new healthcare strategy that involves lots of investing;
- A top health official says Ginkgo Bioworks isn't respecting public health.
If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or tweet @leah_rosenbaum. Let's get to it…
Bridgette Melo, 5, holds the hand of her father, Jim Melo, during her inoculation of one of two reduced 10 microgram doses of the Pfizer BioNTech COVID-19 vaccine during a trial at Duke University in Durham, North Carolina on September 28.
Shawn Rocco/Duke University/Handout via REUTERS
The FDA just authorized Pfizer's COVID-19 shot for kids 5-11 years old, opening a vaccination campaign to younger children
Shawn Rocco/Duke University/Handout via REUTERS
- The FDA has authorized the first coronavirus vaccine for younger children.
- The agency OK'd Pfizer's vaccine for use in 5- to 11-year-old kids.
- The CDC will finish the review process when its advisory panel meets on November 2 and 3.
Samsung Electronics Vice Chairman Jay Y. Lee in Seoul, South Korea.
Kim Hong-Ji/Reuters
While Amazon and Google are building digital-health operations, Samsung is aggressively adding to its healthcare investment portfolio
Kim Hong-Ji/Reuters
- Samsung's venture-capital division has been making a diverse series of digital-health investments.
- Samsung hopes these investments will pave the way for more usage of its devices in healthcare.
- Key areas for investment are health monitoring, wellness, and at-home testing and care.
Former FDA Commissioner Scott Gottlieb, right, is seen on Zoom at a Ginkgo Bioworks panel on biosecurity.
Allison DeAngelis/Insider
Ginkgo Bioworks wanted to tout its COVID-19 testing business. But a top health official said the biotech isn't respecting basic public health after it pushed him to attend an in-person event while sick.
Allison DeAngelis/Insider
- Ginkgo Bioworks gathered health leaders to discuss Biosecurity and preventing pandemics Thursday.
- Ex-FDA Commissioner Scott Gottlieb said Ginkgo wanted him to attend in-person, while sick.
- "It's disappointing to see Ginkgo, which purports to be a healthcare company, not respect these basic public health ethos," he said.
More stories we're reading:
- The FDA told Moderna it needs more time to review use of their COVID-19 vaccine for kids (Insider)
- You probably qualify for a COVID-19 booster already, even if you don't realize it, several health experts say (Insider)
- A new study shows that vaccinated people can still spread the Delta COVID-19 variant, though unvaccinated people are still much more likely to get severely ill (Bloomberg)
- Anti-vaxxers shifted strategies to target the right during the pandemic. But they're coming after young mothers again with a vengeance - right under Facebook's nose. (Insider)
- Here's what we know so far about the 'Delta plus' COVID-19 variant (STAT)
-Leah
Read the original article on Business Insider
Dit artikel is oorspronkelijk verschenen op z24.nl